In conclusion, drawing the molecular signature underlying alterations of insulin signaling in DS is a key challenge to identifying novel drug targets and set-up new prevention strategies aimed to reduce metabolic disorders as well as their impact on cognitive decline in DS. This evidence concerns the gene INS and metabolic disease.